Famotidine for healing and maintenance in nonsteroidal anti- inflammatory drug-associated gastroduodenal ulceration

Hudson, N.; Taha, A S; Russell, R. R. B.; Trye, P; Cottrell, Jeremy J.; Sg, Mann; Swanell, AJ; Sturrock, R D; Hawkey, C. J.

doi:10.1053/gast.1997.v112.pm9178671

Cited by 122 publications

(57 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20,25 However, such evidence does not exist for H 2 RAs, except at high doses. [8][9][10][11] In these trials evaluating the efficacy of acid suppressive co-therapy, the adherence rates to the co-prescribed medication were generally higher than those reported in our analysis, as drug administration occurred under rigorous study conditions rather than in usual clinical practice. Although prospective randomized trials clearly demonstrating that acid suppressive agents reduce the rate of NSAID-associated ulcer complications have not been conducted, it is reasonable (albeit controversial) to suggest that a reduction in NSAID-associated endoscopic ulcers represents at least a semi-quantitative surrogate marker for a reduction in the rate of ulcer complications.…”

Section: Discussioncontrasting

confidence: 60%

“…7 Several blind, randomized, endoscopic trials conducted in high-risk populations have shown that proton pump inhibitors and high-dose H 2 RAs reduce the incidence of NSAID-associated gastro-duodenal ulcers detected at scheduled endoscopy, which can be considered as a surrogate end-point for upper gastrointestinal ulcer complications. [8][9][10][11] Despite the common utilization of H 2 RAs at 'low doses' (e.g. ranitidine 150 mg b.d.…”

Section: Introductionmentioning

confidence: 99%

“…famotidine 40 mg b.d.). [8][9][10][11] In contrast with acid suppression, misoprostol is the only agent that has been proven to reduce the incidence of NSAID-related upper gastrointestinal ulcer complications in a prospective randomized trial. 3 The clinical importance of identifying patients at increased risk and of taking action to prevent/reduce the rate of NSAID-associated upper gastrointestinal complications is reflected in several national treatment guidelines, which recognize that patients at higher risk may require specific interventions to reduce their risk of upper gastrointestinal ulcer complications.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adherence to proton pump inhibitors or H₂‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

Sturkenboom

Burke²,

Tangelder³

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: The efficacy of proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H 2 RAs) prescribed as prophylaxis for NSAID-related upper gastrointestinal (UGI) toxicity is dependent upon patient adherence. Aim: To describe patient adherence to prophylactically prescribed PPIs and H 2 RAs in the clinical setting. Methods: We conducted a retrospective observational cohort study using the Integrated Primary Care Information Project database. The study population consisted of incident non-specific NSAID users prescribed a PPI or H 2 RA specifically as prophylaxis for NSAID-related UGI toxicity. Patients were classified as non-adherent if < 75% of days of NSAID use were covered by one of these agents, and as continuing users after discontinuation of NSAID use if they had a renewed prescription for these agents after their last NSAID prescription. Results: The study cohort comprised 784 patients: 374 with H 2 RAs, 405 with PPIs, and 5 with both PPI and

show abstract

Section: Discussioncontrasting

confidence: 60%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adherence to proton pump inhibitors or H₂‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

Sturkenboom

Burke²,

Tangelder³

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…50 In three studies all had had ulcers recently, but these had healed before randomisation. 47,56,58 In one study no baseline endoscopy was carried out, but some participants had GI symptoms. 53 The baseline risk status of participants varied between studies.…”

Section: Participantsmentioning

confidence: 99%

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of car...

show abstract

“…Famotidine at 80 mg/day, particularly when administered three times a day (TID), maintains gastric pH above important thresholds for both GI healing and prophylaxis 18 . Clinical studies, including randomized controlled trials, have demonstrated that the use of famotidine at a total daily dose of 80 mg during treatment with NSAIDs reduces the risk of endoscopic UGI ulceration and is generally well tolerated 19,20 , offering an alternative to PPIs in appropriate at-risk patients.…”

Section: Introductionmentioning

confidence: 99%

One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension

Bello

Grahn

Ball

et al. 2015

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective:To evaluate the safety of the fixed combination of ibuprofen and famotidine compared with ibuprofen alone from two 24-week, multicenter, double-blind trials designed to evaluate the comparative incidence of endoscopically documented upper gastrointestinal ulcers and a 28-week double-blind extension study. Research design and methods:Safety was analyzed by pooling data from the two double-blind trials and the follow-on study. Safety was assessed by monitoring the incidence, causality, and severity of adverse events (AEs). Results:In the pivotal efficacy and safety trials, discontinuation rates due to any cause and dyspepsia were significantly lower for the ibuprofen/famotidine combination versus ibuprofen alone. Other than dyspepsia, gastrointestinal and cardiovascular AEs of special interest were similar. Events judged to be treatment related were significantly lower with the ibuprofen/famotidine combination (20.6% vs. 25%). In the safety extension population, there were no differences in the discontinuation rates and the reporting of AEs or serious AEs (SAEs) between the two groups. Gastrointestinal-related events were similar between the groups. Incidence of cardiovascular-related AEs of special interest were 11% (ibuprofen/famotidine) and 2% (ibuprofen) (p ¼ 0.06), possibly due to a higher number of rheumatoid arthritis patients in the combination group. Of these, 80% were reports of hypertension (8% ibuprofen/famotidine vs. 2% ibuprofen). Three cases of hypertension in the ibuprofen/famotidine group were considered treatment related. The probability of a cardiovascular event decreased during days 112-167 of treatment and remained low with continued treatment. Conclusions:One-year safety data from two pivotal trials and a long-term extension study indicate that the ibuprofen/ famotidine combination demonstrates a favorable gastrointestinal safety profile and more patients continued on therapy compared to ibuprofen alone. No new safety signals have been identified. These data offer additional evidence supporting a new therapeutic option to improve gastrointestinal safety and adherence for patients who require long-term ibuprofen.

show abstract

Famotidine for healing and maintenance in nonsteroidal anti- inflammatory drug-associated gastroduodenal ulceration

Cited by 122 publications

References 1 publication

Adherence to proton pump inhibitors or H₂‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

Adherence to proton pump inhibitors or H₂‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension

Contact Info

Product

Resources

About

Famotidine for healing and maintenance in nonsteroidal anti- inflammatory drug-associated gastroduodenal ulceration

Cited by 122 publications

References 1 publication

Adherence to proton pump inhibitors or H2‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

Adherence to proton pump inhibitors or H2‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension

Contact Info

Product

Resources

About

Adherence to proton pump inhibitors or H₂‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs

Adherence to proton pump inhibitors or H₂‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs